Avizakimab, formerly known as BOS161721, represents a promising therapeutic approach to treating autoimmune diseases . This biological agent selectively targets IL18, a crucial signaling molecule implicated in https://woodykdvl053227.blog5.net/94986546/avizakimab-a-thorough-exploration-into-bos161721-s-capability